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Summary 
Measles virus after binding to its cell surface human CD46 receptor fuses with the plasma membrane. 
This fusion results in envelope hemagglutinin (H) and fusion glycoprotein (F) incorporated into 
the plasma membrane and injection of the nucleocapsid made of nucleoprotein (NP) into the 
cytosol. The influence of targeting measles virus (MV) to CD46 in the processing and presentation 
of MV H  and NP to antigen specific MHC class II bE d- and bAd-restricted T cell hybridomas 
was explored using murine M12-CD46  B cell transfectants. Parent M12 cells, which lack any 
MV receptor, were unable to present any of these two viral proteins when incubated with MV 
particles. Incubating M12.CD46 cells with 200 ng and 10/zg of MV could strongly stimulate 
H-specific and NP-specific T cells, respectively.  Neosynthesis of MV proteins was not necessary 
since the efficiency of antigen presentation was similar when using ultraviolet-inactivated MV. 
Similar enhancing effects (more than 1,000-fold) on antigen presentation were also observed when 
using purified native H soluble or incorporated into liposomes whereas denaturating H glycoprotein 
resulted in a poor efficiency in T  cell stimulation, M12.CD46 being no more potent than the 
parental M12 counterpart. MV H  and NP presentation efficiency did not depend on MV fusion 
with plasma membrane as revealed by the lack of effect of specific fusion inhibitors. Both MV 
H  and NP presentations were sensitive  to chloroquine inhibition indicating that antigens from 
CD46-mediated captured MV were likely processed in the endosome/lysosome compartment. 
Altogether these data indicate that (a) MV targeting via CD46 has a strong effect on the efficiency 
of antigen presentation by MHC class II, (b) the effect is mediated by the binding of H to CD46, 
and (c) though MV does fuse with plasma membrane, endocytosis, and processing of virus particles 
are also occurring. Since, in humans, CD46 is expressed in almost every tissue including professional 
antigen-presenting  cells,  such  a  targeting  is  likely  to  play  a  crucial  role  in  the  CD4 +  T 
cell-mediated primary immune response against the pathogen in vivo. 
T 
argeting a soluble exogenous antigen to antigen-specific 
B cells via their cell surface Ig (1, 2) or to macrophages 
via their FcR after opsonization with specific antibodies (3) 
result in a strong enhancement of MHC class II-restricted 
antigen presentation to CD4 § T cells. Therefore, the spedfic 
cellular receptor used by an intracellular pathogen to enter 
hosts' cells should play a crucial role in the induction of the 
immune response by facilitating the pathogen capture by the 
APC and the presentation of pathogen-derived antigens by 
MHC class II molecules to specific T cells. We have recently 
identified the human CD46 molecule (membrane cofactor 
protein), a regulator of the complement activation (4), as a 
receptor for measles virus (MV) (5, 6). MV is a pleiomorphic, 
enveloped and negative, single strand RNA virus belonging 
to the Morbillivirus genus and Paramyxovirus family. The 
envelope is made of two glycoproteins, hemagglutinin (H) 
and fusion protein (F) responsible for MV attachment and 
fusion with the plasma membrane of target cells. This fusion 
results in H  and F incorporation into the plasma membrane 
and in the delivery into the cytosol of the nucleocapsids es- 
sentially made of RNA and nucleoprotein (NP). Then viral 
replication can occur. Thus, MV infection does not require 
virus particle endocytosis and an acidic pH for fusion as is 
the case for influenza virus. MV is the causative agent of the 
measles  disease in humans and can only infect human and 
some simian cells. Expression of CD46 allows mouse M12 
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to form syncitium when both measles H  and F glycoprotein 
are expressed after infection with MV or with recombinant 
vaccinia virus  encoding  H  and  F  glycoproteins,  and  (c)  to 
replicate MV  (6).  The aim of the present  work was  (a) to 
look for a receptor-mediated enhancement of MHC class II-re- 
stricted H  and NP presentation when MV is targeted to CD46, 
(b) to test the ability of H  to bind to CD46, and (c) to deter- 
mine whether after CD46  targeting of MV, H, and/or NP 
antigen presentation by MHC class II involves an endosomal 
pathway  although  MV  can  fuse  at  the  plasma membrane. 
assay. After incubation for 20 h at 37~  IL-2 production in super- 
natants was measured using the MTT colorimetric CTL-L2 bio- 
assay (11). All the experiments were repeated several times with 
similar results and the standard deviation between replicates  was 
usually well below 5%. Some experiments were done in the pres- 
ence of 50/~M chloroquine added to APCs before the antigen and 
maintained throughout  the bioassay as described elsewhere (12). 
These chloroquine concentrations were well tolerated by the cells 
and did not affect the CTL-L2 bioassay (12). In other experiments, 
10/~M of the Z-D-Phe-Phe-Gly  and Gly-Phe-Phe tripeptides (Neo- 
syst~mes, Strasbourg, France) or c155 anti-H and cl anti-F ascitis 
fluid in a final dilution of 1:50 were added during the T cell stimu- 
lation. 
Materials and Methods 
Measles Virus, Viral Proteins, and Antibodies.  MV (Halle strain) 
was produced and purified as previously described (7). In some ex- 
periments, MV was UV-irradiated before use by 15 rain exposure 
at 5 cm from a 254-nM UV-lamp. UV-treatment abolished tran- 
scription and replication of the viral genome without inhibiting 
its binding and fusion abilities.  Native H glycoprotein was purified 
from Vero cells infected with MV and incorporated into liposomes 
as previously described (7). Denaturated H glycoprotein was purified 
under  strong  denaturing  conditions  in  the  presence of sodium 
dodecylsulfate and mercaptoethanol from insect cells infected with 
a recombinant baculovirus encoding H glycoprotein according to 
a procedure to be described elsewhere (Cretin F., I. Chr6tien,  I. 
Fugier-Vivier,  D. Gerlier, and C. Rabourdin-Combe,  in prepara- 
tion). It differed from the purified native H by its lack of reactivity 
with conformational anti-H mAbs such as c155 and it was no longer 
in  dimeric  form due  to  the  use of reducing  conditions  during 
purification. A cytosolic extract of High-Five insect cells infected 
with a recombinant baculovirus encoding measles  NP was used 
as a source of crude NP (BI-NP). High-Five insect cells were in- 
fected with 5 PFU/cell of recombinant AcNPVN baculovirus ob- 
tained according to a published procedure (8).  3 d later,  the cells 
were washed, pelleted,  and disrupted in  1 mM EDTA, 0.5  mM 
Tris/HC1 buffer,  pH  7.5,  supplemented  with  a  cocktail  of an- 
tiproteases for 0.5  h  on ice.  After centrifugation  at  10,000  rpm 
for 1 h, the supernatant was kept frozen at  -20~  until use. NP 
usually represents between 50 and 80% of the total protein present 
in the cell extract. For some experiments, NP was immunopurified 
after adsorption on a batch of anti-NP c125 monoclonal antibody 
coupled  to CNBr  activated Sepharose 4B (Pharmacia,  Uppsala, 
Sweden) and elution using 0.2 M HCl-glycine buffer, pH 2.5. The 
purity of the NP preparation was assessed after SDS-PAGE elec- 
trophoresis and silver staining. MV H-, NP-, and F-specific anti- 
bodies (c155, c125, and B22-F5, respectively) were kindly provided 
by T. E Wild and P. Giraudon (Institut Pasteur de Lyon and Univer- 
sit6 de Lyon, France,  respectively) (9,  10). 
Cell Lines.  M12.CD46 cells expressing human CD46 have been 
obtained after transfection with the plRV-CD46 expression vector 
of the mouse B lymphoma M12.4.1  cells (6).  The H-specific and 
I-Ed-restricted T cell hybridoma TH5.124 has been previously de- 
scribed (11). The NP-specific and I-Ad-restricted TNP.408 T cell 
hybridoma was isolated using a procedure previously described (11). 
T Cell Stimulation Assay.  Antigen stimulation of the T cell hy- 
bridomas was performed by cocultivating  10  s hybridoma T  cells 
with 3  x  104 H-2  d M12.4.1  or M12.CD46 B cells in the presence 
or absence of serial dilutions of antigen in a final volume of 200 
/A in 96-well microplates. In some experiments, M12.HELs3 cells 
that secrete hen egg lysozyme (11) were used instead of M12.4.1 
cells.  The secretion of lysozyme did not interfere with  the bio- 
Results 
Expression  of CD46 by Murine APC Is Required for E~icient 
Presentation of Virus Proteins by MHG Class II Molecules.  When 
incubated  with  infectious  MV,  M12.CD46  cells were very 
efficient in presenting H  glycoprotein to the I-Ed-restricted 
TH5124, whereas M12 parent cells were unable to stimulate 
these T  cells (Fig.  1 a). Incubating M12.CD46  cells with as 
few as 200 ng of virus was sufficient to stimulate TH5124 
T  cells. Viral replication and neosynthesis of H  glycoprotein 
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Figure  1.  Presentation of CD46-targeted MV proteins to H-specific  and 
NP-specific T cell hybridomas. Ability to M12 (squares) and M12.CD46 
(triangles) cells to stimulate I-E'L-restricted  and H-specific  TH5.124 (a and 
c) or I-A  a restricted NP-specific TNP.408 (b) when fed with (a and b) in- 
fectious MV (solid  squares and triangles) or UV-inactivated  MV (open squares 
and triangles) or (c) UV-inactivated MV in the presence of anti-H (solid 
circles) or anti-F (open circles) antibodies. The T cell stimulation was mea- 
sured by quantitating  the 1I.-2 production using the CTLL-2 and MTT 
bioassay. 
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Efficiency  of the CD46-mediated presentation to TH5.124 
T cells of (a) purified native H, (b) purified native H in liposomes, or (c) 
purified denatured H by M12 (open squares) and M12.CD46 (solid squares). 
known to occur in M12.CD46 cells (6) were not necessary 
for efficient presentation because T  cells were stimulated as 
efficiently when MV was UV-inactivated (Fig.  1 a). Efficient 
presentation was not limited to the viral envelope H  glyco- 
protein since NP-specific and I-Aa-restricted TNP.408 T cell 
hybridomas were stimulated in the presence of M12.CD46 
but not M12 fed with  UV-MV (Fig.  1 b).  Allowing MV 
genome transcription and replication in M12.CD46 did not 
result in further enhancement  of NP presentation  (data not 
shown). These results indicated that MV captured via CD46 
provided an optimal amount of both virions H and NP pro- 
teins for antigen processing and presentation by MHC class 
II molecules. In an attempt to mimic such a capture effect, 
M12 cells that express FcR3' (13) were incubated with MV 
in  the presence of anti-H  or anti-F  mAbs. 
Indeed,  the opsonization  of MV particles by antibodies 
resulted in some presentation  of both viral structural  pro- 
teins H  (Fig.  1 c) and NP (data not shown) by MHC class 
II molecules. The efficiency of antibody-mediated capture of 
MV was however far lower than the CD46 mediated capture 
(compare Fig.  1 a and c) in agreement with the poor inter- 
nalization of the FcRylIbl receptor isoform expressed in B 
cells (14). 
CD46 Mediates Effcient Presentation of Purified Native But 
Not Denatured H Glycoprotein.  The MV H  envelope glyco- 
protein has long been thought  to be the binding  structure 
used by MV to attach to its target cells. To verify that MV 
H  can directly bind to CD46,  the efficiency of M12.CD46 
to present purified native H glycoprotein to TH5.124 T cells 
was  tested￿9  Indeed,  M12.CD46  requires  ~,100-fold  less 
purified soluble H than its parental M12 counterpart to stimu- 
late TH5.124 T cells with the same efficiency (Fig.  2 a). The 
difference was even higher when purified H  were given to 
the APC as liposomes (Fig.  2 b). This was due both to the 
higher efficiency of M12.CD46 cells and to the poor ability 
of M12 cells to present H  in a particulate form as observed 
with MV particles. M12.CD46 was so efficient at capturing 
H-liposomes that as little as 10 ng/ml of H glycoprotein (i.e., 
an  H  concentration  around  0.06  pM  since  the  Mr  of H 
homodimer is m160) was sufficient to give a strong stimula- 
tory signal  to TH5.124  T  cells.  This antigen  presentation 
efficiency was comparable to the high efficiency of endoge- 
nous H presentation by M12.H transfectants (data not shown 
and 11). This was >100 times less than the amount of purified 
native H  required by parental  M12 cells  to stimulate these 
T  cells with the same efficiency (compare Fig.  2, a and b). 
In contrast, M12.CD46 and M12 cells were equally (and rel- 
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Figure 3.  CD46-mediated efficient presen- 
tation of MV H  (a and b) and NP (c and d) 
proteins is not sensitive to specific fusion in- 
hibiting agents. M12.CD46 cells were incubated 
with various amounts of UV-MV alone (open 
squares), or (a and c) in the presence of anti-H 
(open triangles) and anti-F (solid triangles) anti- 
bodies, or (b and d) 10/~M of Z-D-Phe-Phe-Gly 
(solid circles) and Gly-Phe-Phe (open circles) tripep- 
tides,  and used to stimulate TH5.124 (a and 
b) and TNP.408  (c and d) T  cells. 
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glycoprotein. In addition, the dose-response curves were similar 
to that observed for purified native H presented by M12 cells 
(compare Fig. 2, a and c). This indicates that native H glyco- 
protein has  the ability to bind directly to CD46. 
Efficient Presentation of  MV Antigens Targeted to CD46 Does 
Not Require  MV Fusion at the Cell Membrane  but Involves a 
Chloroquine Sensitive Pathway.  For cell infection, MV enters 
its target by fusing with the plasma cell membrane and does 
not require endocytosis. This fusion process involves both 
H and F glycoproteins, F glycoprotein having the fusogenic 
properties (6, 15). To test the role of the fusion, anti-F mAbs 
(10) and the tripeptide z-D-Phe-Phe-Gly (16) were used as 
specific fusion inhibitors.  Whereas both anti-F antibodies and 
z-o-Phe-Phe-Gly tripeptide completely abrogated the H + F 
induced cell-cell and MV-cell fusion (data not shown) they 
left intact the efficiency of MV H  and NP presentation by 
M12.CD46 to TH5.124 and TNP.408 T cell hybridomas (Fig. 
3). The tripeptide Gly-Phe-Phe, which has no effect on MV- 
induced fusion, was used as a negative control. The lack of 
inhibition by the anti-F antibody could have been compen- 
sated for by the opsonizing effect and targeting to the M12 
FcR3'. This is unlikely, since the efficiency of MV capture 
in the presence of anti-F is very limited (see Fig.  1 c). Sur- 
prisingly, when anti-H antibodies were used as a control, 
they were found to significantly decrease the efficiency of MV 
H  presentation but not that of MV NP presentation (Fig. 
3,  a  and  c).  This  suggests  that  anti-H  antibodies  could 
specifically protect H glycoproteins from proteolytic degra- 
dation as previously observed by others (17). 
Endosomal processing is inhibited by lysosomotropic agents, 
and the effect of chloroquine on the ability of M12.CD46 
cells to present MV H and NP proteins was then tested. Presen- 
tations of H  and NP from MV particles to TH5.124  and 
TNP.408 T cells, respectively, were almost completely abol- 
ished in the presence of 50 #M of chloroquine (Fig. 4). Similar 
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Chloroquine sensitivity of MV H  and MV NP presentation 
by M12.CD46 cells.  Purified native MV (a and b) were used to stimulate 
TH5.124  (a)  or TNP.408  (b) T  cells in the absence (open squares) or in 
the presence of 50-/zM (solid triangles) chloroquine. 
resuhs were obtained when using soluble NP, purified H in 
liposomes, or antibody-opsonized MV targeted to FcR'y of 
M12 cells (data not shown). 
Discussion 
By comparing mouse B cells devoid of cell surface expres- 
sion of MV receptor with their counterparts expressing the 
human CD46,  it is shown that targeting the virus to the 
APC via its cellular receptor dramatically increases (>1,000- 
fold) the efficiency of viral antigen presentation by MHC class 
II molecules. This effect is due to the efficient uptake of virus 
particle following the interaction of the viral envelope H gly- 
coprotein and CD46 molecules as firstly reported here. It does 
not depend on the presentation of neosynthesized viral pro- 
teins since the UV-inactivation of MV did not change the 
efficiency of antigen presentation to CD4 + T  cells. 
The coexpression of MV H, MV F, and CD46 glycopro- 
teins is sufficient to induce fusion between two cell mem- 
branes leading to the formation of syncitia (6). This fusion 
process is likely to be similar to the fusion between MV enve- 
lope and cell membrane allowing the MV nucleocapsids to 
enter the cytosol where viral replication occurs (6). This raises 
the possibility that MV fusion at the cell surface of M12.CD46 
might be involved in the efficiency of MV antigen presenta- 
tion. All the experimental data that have been obtained so 
far argue against this hypothesis. (a) Potent and specific in- 
hibitors of MV H-and F-mediated fusion after binding to 
CD46  virus  receptor  such  as  anti-F  antibodies  (10) and 
z-o-Phe-Phe-Gly tripeptide which is homologous to the hy- 
drophobic NH2 terminus of the F1 subunit of F glycopro- 
rein (16) has no effect whatsoever on the ability of M12.CD46 
cells to present MV proteins.  (b) The CD46-mediated en- 
hancing effect on MV antigen presentation was observed using 
purified soluble native H  glycoprotein or H liposomes that, 
as shown previously (7), do not contain any detectable F gly- 
coprotein strictly required for the fusion. Moreover, the chlo- 
roquine sensitivity of MV H and MV NP antigen presenta- 
tion  strongly  suggests  that  the processing of these  viral 
structural antigens occurs in an acidic endosomal/lysosomal 
compartment after receptor-mediated endocytosis of some MV 
particles although MV can fuse with plasma membrane. So, 
CD46-mediated enhancement of MV antigen presentation 
is likely to involve an endosomal processing pathway as ob- 
served for antigen targeted to a plasma membrane protein 
such as cell surface Ig of specific B cells or FcR of macro- 
phages (1-3,  14,  17). 
Comparison between soluble native H  and H  liposomes 
shows that the latter was more efficient in delivering H  an- 
tigen for processing by M12.CD46  cells. A likely explana- 
tion is that the liposome vector allows the capture by a single 
APC of several H  glycoproteins contained in one vesicle as 
soon as a single or few H glycoproteins have bound to CD46 
molecules. This may partly explain the strong enhancing effect 
of liposome vector on the immunogenicity of a cell surface 
murine retrovirus glycoprotein previously reported by one 
of us (18). It has been previously reported that, in vitro, mac- 
rophages but not B cells can mediate presentation of (untar- 
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cytic activity (19, 20). Accordingly, M12 B cells were found 
to be almost unable to present MV antigens when in partic- 
ulate form (virions, H liposome). In contrast, when H lipo- 
somes (and virions) were targeted to the cell surface CD46, 
M12.CD46 B cells became able to present H  to MHC class 
II-restricted T cells with a high efficiency  in agreement with 
the recent work of Grivel et al.  (21) showing that B cells 
can endocytose targeted liposome-associated  antigen. As a con- 
sequence, phagocytic activity of APCs may not be required 
for efficient presentation of particulate antigens by MHC class 
II provided that receptor-mediated binding and internaliza- 
tion can occur. 
We hypothesize that, in vivo, efficient priming of CD4 + 
T cell-mediated immune response could mainly rely on pep- 
tides derived from exogenous antigens targeted to the APC 
(1-3, 14, 17, this paper) and/or endogenous antigens synthe- 
sized and translocated into the endoplasmic reticulum within 
the APC (11). Human CD46 is expressed on every cell type 
except on erythrocytes (4,  6).  Thus,  human  CD46 + den- 
dritic cells and macrophages that are likely to be the main 
APC involved in the in vivo primary stimulation of MHC 
class II-restricted CD4 §  T  cells should be able  to capture 
efficiently MV leading to a strong primary immune stimula- 
tion even if the amount of virus and/or its infectivity is limited. 
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